Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
07:30am, Tuesday, 10'th Aug 2021
NEW YORK, Aug. 10, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin,
7 Stocks to Buy if You Think Alternative Therapies Are the Future
12:52pm, Monday, 02'nd Aug 2021
Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments. The post 7 Stocks to Buy if You Think Alternative Therapies Are the Fut
MindMed Interim CEO on the growing competition in psychedelics industry
01:10pm, Sunday, 01'st Aug 2021
This segment originally aired on July 29, 2021. Robert Barrow, MindMed Interim CEO, joins Yahoo Finance to discuss then transition in MindMed's CEO, future outlook for the company and the psychedelics
MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects
10:24am, Thursday, 29'th Jul 2021
Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such as ayahuasca, giving promising results in the quest for alternative treatments
Mind Medicine Has More Obstacles Than Opportunities
09:49am, Tuesday, 20'th Jul 2021
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business. The post Mind Medicine Has More Obstacles Than Opportunities app
7 Top-Rated Pharmaceutical Companies to Invest In for July
09:15am, Friday, 09'th Jul 2021
Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest I
MindMed Stock Is Overvalued and Too Risky to Own
03:32pm, Thursday, 08'th Jul 2021
MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about. The post MindMed Stock Is Overvalued and Too Risky to Own appeared f
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company
08:20am, Thursday, 08'th Jul 2021
NEW YORK, July 8, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in he
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
02:35pm, Friday, 02'nd Jul 2021
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.
Psychedelics-Focused MindMed Joins FTSE Russell 3000 Index, 'A True Honor'
02:31pm, Tuesday, 29'th Jun 2021
A psychedelics-focused medicine company MindMed (NASDAQ: MNMD) reported Monday that has been added to the FTSE Russell 3000 index, effective June 25th. The FTSE Russell 3000 index measures the perf
MindMed Can Play a Big Role in the Growing Mental Wellness Industry
01:32pm, Monday, 28'th Jun 2021
MNMD stock is positioned for long-term growth as its LSD, MDMA, and Psilocybin-based treatments have a huge addressable mental wellness market. The post MindMed Can Play a Big Role in the Growing Ment
Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics'
12:50pm, Monday, 28'th Jun 2021
Mind Medicine (MindMed) Inc (NASDAQ:MNMD) shares traded higher by 3.3% on Monday after one analyst initiated bullish coverage of the psychedelics stock. The Analyst: Maxim analyst Jason McCarthy init
MindMed Included in FTSE Russell 3000® Index
07:30am, Monday, 28'th Jun 2021
NEW YORK, June 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company announced that effective Friday, June 25th, 2021, MindMed has been
7 Best Penny Stocks to Buy Now for Potential 10X Gains
02:19pm, Thursday, 24'th Jun 2021
Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board
07:30am, Wednesday, 23'rd Jun 2021
NEW YORK, June 23, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition o
